drugset / Trial / NCT04887857
A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-486 (ONUREG®) in combination with venetoclax in relapsed and/or refractory Acute Myeloid Leukemia (AML) and newly diagnosed AML.
Timeline
- Start
- 2021-12-01
- Primary completion
- 2024-01-08
- Completion
- 2024-01-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CC-486 | Unknown | — | Oral |
| Subject | Venetoclax | Small molecule | — | — |